SBIR Phase I: Design And Production Of IgG Fc Carrier Scaffolds With Increased Payload Capacity

这个小企业创新研究（SBIR）第一阶段项目将开始，以解决目前在肽药物输送和化学蛋白质结合的一些挑战。使用Redwood Bioscience的专利技术平台，一种蛋白质工程技术，可以将含有独特手柄的非规范氨基酸插入任何感兴趣的蛋白质中。这种独特的手柄，一种“醛标签”，可以用例如合成的治疗肽进行化学加工。在Redwood Bioscience，这种蛋白质工程技术用于生成通用蛋白质支架，IgG Fc结构域，易于化学加工，产生同质产品，可用作持久的蛋白质-肽疗法。重要的是，使用这种技术，它是可能的，以精心制作的蛋白质支架与多个标签的小分子的附件，增加潜在的有效载荷能力的载体scaffold.The更广泛/商业的影响，这项研究是最好的类治疗的发展与增加的有效载荷能力和由此产生的交付足够高浓度的所需药物。 这是对现有技术的重大和实质性改进。此外，通过？拓展蛋白质药物的化学空间，红木？该技术在开发具有独特蛋白质化学结构的新型混合药物中具有应用，包括具有增强的有效载荷能力的多价结构。该公司计划扩大其同类最佳治疗化合物的管道，用肽或小分子候选物装载Fc支架载体蛋白，这些肽或小分子候选物被确定为目前PK特征较差的潜在治疗药物。

This Small Business Innovation Research (SBIR) Phase I project will begin to address some of the current challenges in peptide drug delivery and chemical protein conjugation. Using Redwood Bioscience's patented technology platform, a protein engineering technique, it is possible to insert a non-canonical amino acid containing a unique handle into any protein of interest. This unique handle, an "aldehyde tag", can be specifically elaborated chemically with a synthetic therapeutic peptide, for example. At Redwood Bioscience, this protein engineering technology is used to generate universal protein scaffolds, IgG Fc domains, that are easy to chemically elaborate, result in a homogenous product and can be used as long lasting protein-peptide therapies. Importantly, using this technology it is possible to elaborate the protein scaffolds with multiple tags for small molecule attachment, increasing the potential payload capacity of the carrier scaffold.The broader/commercial impact of this research is the development of best in class therapeutics with increased payload capacity and the resulting delivery of sufficiently high concentrations of a desired drug. This is a significant and substantial improvement over the current technologies available. Moreover, through ?expanding the chemical space of protein drugs?, Redwood?s technology has application in developing novel hybrid drugs with unique protein-chemical architectures, including multivalent constructs with enhanced payload capacity. The company plans to expand its pipeline of best in class therapeutic compounds, loading Fc scaffold carrier proteins with peptide or small molecule candidates, identified as potential therapeutics currently suffering from poor PK profiles.